Bioavailability Development Genotype In-Vitro 
The Pharma Data
DECEMBER 9, 2020
Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.
Drug Discovery World
OCTOBER 18, 2022
Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). . Context .
Expert insights. Personalized for you.
52 
Let's personalize your content